248 related articles for article (PubMed ID: 32942295)
1. Predictors of Chronic LH-Testosterone Axis Suppression in Male Macroprolactinomas With Normoprolactinemia on Cabergoline.
Sehemby M; Lila AR; Sarathi V; Shah R; Sankhe S; Jaiswal SK; Ramteke-Jadhav S; Patil V; Shah N; Bandgar T
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32942295
[TBL] [Abstract][Full Text] [Related]
2. Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma.
Rudman Y; Duskin-Bitan H; Masri-Iraqi H; Akirov A; Shimon I
Pituitary; 2022 Dec; 25(6):882-890. PubMed ID: 36036309
[TBL] [Abstract][Full Text] [Related]
3. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
Sibal L; Ugwu P; Kendall-Taylor P; Ball SG; James RA; Pearce SH; Hall K; Quinton R
Pituitary; 2002; 5(4):243-6. PubMed ID: 14558672
[TBL] [Abstract][Full Text] [Related]
4. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment.
Ribeiro RS; Abucham J
Eur J Endocrinol; 2009 Jul; 161(1):163-9. PubMed ID: 19359408
[TBL] [Abstract][Full Text] [Related]
5. Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists.
Al Dahmani KM; Almalki MH; Ekhzaimy A; Aziz F; Bashier A; Mahzari MM; Beshyah SA
Pituitary; 2022 Aug; 25(4):658-666. PubMed ID: 35793046
[TBL] [Abstract][Full Text] [Related]
6. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
7. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas.
George LD; Nicolau N; Scanlon MF; Davies JS
Clin Endocrinol (Oxf); 2000 Nov; 53(5):595-9. PubMed ID: 11106920
[TBL] [Abstract][Full Text] [Related]
8. Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline.
Walia R; Bhansali A; Dutta P; Khandelwal N; Sialy R; Bhadada S
Indian J Med Res; 2011 Sep; 134(3):314-9. PubMed ID: 21985814
[TBL] [Abstract][Full Text] [Related]
9. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
[TBL] [Abstract][Full Text] [Related]
10. Long-term use of clomiphene in male macroprolactinomas with persistent hypogonadism.
Stumpf MAM; Galliano SA; Bueno CBF; Glezer A
Endocrine; 2024 Apr; ():. PubMed ID: 38578401
[TBL] [Abstract][Full Text] [Related]
11. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Tirosh A; Benbassat C; Shimon I
Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
[TBL] [Abstract][Full Text] [Related]
12. Prolactin ≤1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy.
Kim D; Ku CR; Kim K; Jung H; Lee EJ
Eur J Endocrinol; 2020 Feb; 182(2):177-183. PubMed ID: 31770105
[TBL] [Abstract][Full Text] [Related]
13. Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: Does size really matter?
Rudman Y; Duskin-Bitan H; Manisterski Y; Pertzov B; Akirov A; Masri-Iraqi H; Shimon I
Clin Endocrinol (Oxf); 2021 Oct; 95(4):606-617. PubMed ID: 34160838
[TBL] [Abstract][Full Text] [Related]
14. Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression.
Shimon I; Benbassat C; Tzvetov G; Grozinsky-Glasberg S
Pituitary; 2011 Mar; 14(1):11-5. PubMed ID: 20717729
[TBL] [Abstract][Full Text] [Related]
15. Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma.
Kim K; Park YW; Kim D; Ahn SS; Moon JH; Kim EH; Lee EJ; Ku CR
J Clin Endocrinol Metab; 2021 Jan; 106(2):e615-e624. PubMed ID: 33079168
[TBL] [Abstract][Full Text] [Related]
16. Male prolactinomas presenting with normal testosterone levels.
Shimon I; Benbassat C
Pituitary; 2014 Jun; 17(3):246-50. PubMed ID: 23756784
[TBL] [Abstract][Full Text] [Related]
17. Macroprolactinoma-Induced Syndrome of Inappropriate Antidiuresis and Its Reversal with Dopamine Agonist Therapy.
Schlegel A
Lab Med; 2022 Sep; 53(5):537-539. PubMed ID: 35552737
[TBL] [Abstract][Full Text] [Related]
18. Giant prolactinoma in Asian-Indians: A single-center experience from Western India.
Kumar S; Memon SS; Lila AR; Sarathi V; Sehemby M; Karlekar M; Sankhe S; Thakkar H; Patil VA; Shah N; Bandgar T
Ann Endocrinol (Paris); 2023 Dec; 84(6):711-718. PubMed ID: 37866429
[TBL] [Abstract][Full Text] [Related]
19. Combined cabergoline and recombinant human growth hormone treatment of an adolescent with a macroprolactinoma causing GH deficiency.
Cesario F; Borretta G; Meineri I; Muratori M; Pizzocaro A; Beck-Peccoz P
J Pediatr Endocrinol Metab; 1997; 10(2):231-6. PubMed ID: 9364359
[TBL] [Abstract][Full Text] [Related]
20. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
Andrysiak-Mamos E; Kaźmierczyk-Puchalska A; Zochowska E; Sowińska-Przepiera E; Sagan L; Kojder I; Syrenicz A
Pomeranian J Life Sci; 2015; 61(3):263-9. PubMed ID: 27344867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
